Company Basilea Pharmaceutica AG

Equities

BSLN

CH0011432447

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per region

Ratings for Basilea Pharmaceutica AG

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Swiss Exchange Other stock markets 11:31:51 2024-04-24 am EDT			5-day change	1st Jan Change
40.55 ^CHF	-1.70%		-2.76%	+14.87%

Apr. 09	Basilea Pharmaceutica Receives Grant for Antibiotics Program	MT
Apr. 04	Stocks Close in Green as Swiss Inflation Unexpectedly Slows	MT

Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.

Number of employees: 147

CHF in Million	2022	Weight	2023	Weight	Delta
Innovative Pharmaceutical Products 100.0 %	148	100.0 %	158	100.0 %	+6.68%

CHF in Million	2022	Weight	2023	Weight	Delta
Ireland 43.6 %	41	27.9 %	69	43.6 %	+66.34%
Japan 37.8 %	64	43.3 %	60	37.8 %	-6.87%
Uruguay 6.5 %	7	5.0 %	10	6.5 %	+37.84%
United States 3.9 %	10	6.6 %	6	3.9 %	-37.76%
Sweden 2.5 %	3	2.2 %	4	2.5 %	+21.87%
Canada 2.3 %	3	1.9 %	4	2.3 %	+28.57%
China 1.5 %	-	-	2	1.5 %	-
Jordan 1.1 %	3	1.8 %	2	1.1 %	-33.33%
Switzerland 0.9 %	2	1.6 %	1	0.9 %	-41.67%

Managers	Title	Age	Since
David Veitch CEO	Chief Executive Officer	59	14-08-31
Adesh Kaul DFI	Director of Finance/CFO	50	08-12-31
Gerrit Hauck CTO	Chief Tech/Sci/R&D Officer	60	18-04-30
Marc Engelhardt CTO	Chief Tech/Sci/R&D Officer	60	09-12-31
Laurenz Kellenberger CTO	Chief Tech/Sci/R&D Officer	57	99-12-31
Peer Nils Schröder IRC	Investor Relations Contact	-	-
Damian Heller LAW	General Counsel	58	14-12-31
Ursula Eberhardt HRO	Human Resources Officer	62	05-12-31

Members of the board	Title	Age	Since
Nicole Onetto BRD	Director/Board Member	71	17-04-26
Leonard Kruimer BRD	Director/Board Member	66	21-12-31
Alf Gunnar Martin Nicklasson BRD	Director/Board Member	69	13-04-08
Domenico Scala CHM	Chairman	58	11-11-28
Carole A. Sable BRD	Director/Board Member	62	23-04-26
Thomas Werner BRD	Director/Board Member	68	11-11-28

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	13,079,793	11,974,303 ( 91.55 %)	1,098,157 ( 8.396 %)	91.55 %

Name	Equities	%	Valuation
BASILEA PHARMACEUTICA AG 8.332 %	1,091,643	8.332 %	46 M CHF
Black Creek Investment Management, Inc. 5.066 %	663,670	5.066 %	28 M CHF
CI Investments, Inc. 4.901 %	642,065	4.901 %	27 M CHF
Braginsky Family Office AG 2.990 %	391,677	2.990 %	16 M CHF
ACATIS Investment Kapitalverwaltungsgesellschaft mbH 2.539 %	332,689	2.539 %	14 M CHF
Argenta Spaarbank NV 0.7119 %	93,267	0.7119 %	4 M CHF
Bank J. Safra Sarasin AG (Investment Management) 0.6521 %	85,439	0.6521 %	4 M CHF
Saint Olive Gestion SNC 0.5343 %	70,000	0.5343 %	3 M CHF
Apo Asset Management GmbH 0.2405 %	31,511	0.2405 %	1 M CHF
Helaba Invest Kapitalanlagegesellschaft mbH 0.1815 %	23,773	0.1815 %	993 731 CHF

Name	Equities	%	Valuation
BASILEA PHARMACEUTICA AG 8.33%	1,091,643	8.33%	45,631,573 $

Basilea Pharmaceutica AG

Hegenheimermattweg 167b

4123, Allschwil

+41 61 606 11 11

http://www.basilea.com

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

40.55 CHF

Average target price

70.58 CHF

Spread / Average Target

+74.06%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
BASILEA PHARMACEUTICA AG	+14.87%	544M
IQVIA HOLDINGS INC.	+4.09%	43.43B
LONZA GROUP AG	+47.81%	41.69B
MODERNA, INC.	+9.45%	41.31B
CELLTRION, INC.	-10.92%	27.14B
ICON PUBLIC LIMITED COMPANY	+9.32%	25.28B
ALNYLAM PHARMACEUTICALS, INC.	-24.87%	18.47B
MEDPACE HOLDINGS, INC.	+29.70%	12.59B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.28%	12.33B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.03B

Other Biotechnology & Medical Research